[Seite 15↓]

Literatur

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401: 282-286

2. Bani D. Relaxin: a pleiotropic hormone. Gen. Pharmacol. 1997; 28: 13-22

3. Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br. J. Pharmacol. 2000; 130: 1865-1870

4. Bourassa MG, Gurie O, Bangdiwala SJ. Natural history and patterns of current practice in heart failure. J. Am. Coll. Cardiol. 1992; 22(Suppl A): 14A-19A

5. Cheng CP, Onishi K, Ohte N, Suzuki M, Little WC. Functional effects of endogenous bradykinin in congestive heart failure. J. Am. Coll. Cardiol. 1998; 31: 1679-1686

6. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N. Engl. J. Med. 1962; 267: 650–654

7. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc. Natl. Acad. Sci. U S A 1998; 95: 15803-15808

8. Cowie MR, Wood DA, Coats AJS, Thompson SG, Poole-Wilson PA, Suresh V. Incidence and aetiology of heart failure. A population based study. Eur. Heart J. 1999; 20: 421-428

9. Danielson LA, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J. Clin. Invest. 1999; 103: 525-533

10. De Bold AJ, Bruneau BG, Kuroski de Bold ML. (1996) Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc. Res. 1996; 31: 7-18

11. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359: 1990-1997

12. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645-651

13. Goldsmith LT, Weiss G, Steinetz BG. Relaxin and its role in pregnancy. Endocrinol. Metab. Clin. North Am. 1995; 24: 171-186


[Seite 16↓]

14. Hisaw FL. Experimental relaxation of the pubic ligament of guinea pig. Proc. Soc. Exp. Biol. Med. 1926; 23: 661–663

15. Jougasaki M, Wei CM, McKinley LJ, Burnett JC Jr. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995; 92: 286-289

16. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol. 2002; 85: 195-197

17. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am. Heart J. 1991; 121: 951-957

18. Katz AM. Heart Failure: pathophysiology, molecular biology, and clinical management. 2nd Ed. Lippincott Williams & Wilkins, Philadelphia 2002.

19. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem. Biophys. Res. Commun. 1993; 192: 553-560

20. Kojima M. The role of antidiuretic hormone in congestive heart failure. Jpn. Circ. J. 1966; 30: 525-538

21. Lip GYH, Gibbs CR, Beevers DG. ABC of heart failure. Aetiology. Br. Med. J. 2000; 320: 104-107

22. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Cardiol. 1992; 20: 248-254

23. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-2199

24. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc. Natl. Acad. Sci. U S A 1980; 77: 5021-5024

25. Raine AE, Erne P, Burgisser E, Muller FB, Bolli P, Burkart F, Buhler FR. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N. Engl. J. Med. 1986; 315: 533-537

26. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet 2002; 360: 545-546


[Seite 17↓]

27. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2002; 346: 896-903

28. Stangl K, Dschietzig T, Richter C, Laule M, Stangl V, Tanis E, Baumann G, Felix SB. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy. Circulation 2000; 102: 1132-1138

29. Stangl K, Dschietzig T, Richter C, Stangl V, Bartsch C, Zurbrugg HR, Pregla R, Baumann G, Felix SB, Laule M. Cessation of pulmonary and coronary secretion of adrenomedullin peptides in the progression of human heart failure. Horm. Metab. Res. 2002; 34: 81-86

30. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992; 85: 510-517

31. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13

32. The CONSENSUS TRIAL STUDY GROUP. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 1987; 316: 1429–1435

33. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007

34. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N. Engl. J. Med. 1991; 325: 293–302

35. Unemori EN, Amento EP. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J. Biol. Chem. 1990; 265: 10681-10685

36. Unemori EN, Erikson ME, Rocco SE, Sutherland KM, Parsell DA, Mak J, Grove BH. Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum. Reprod. 1999; 14: 800-806

37. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415


[Seite 18↓]

38. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B- type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195–203

39. Zsebo KM. Development of recombinant human relaxin. Clinical experience in scleroderma … and beyond. In: Proceedings of the 3rd International Conference on Relaxin and Related Peptides 2000 (Broome, Australia), pp. 273 – 281, Tregear G. W., Ivell R., Bathgate R. A. and Wade J. D. (eds.), Kluwer Academic Publishers, Dordrecht, The Netherlands.


[Seite 19↓]


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 3.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
13.01.2004